MPLT — MapLight Therapeutics, Inc.
Price · 2025-10-27 → 2026-08-21
206 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2025-10-27.
Performance
Technicals
Others in Healthcare
Measured signals that fired on MPLT
| date | signal | measured base rate |
|---|---|---|
| 2026-07-27 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-07-17 | Cluster sale: three or more insiders insider | -0.37% over 21 days · t = -3.38 · n = 21,542 statistically distinguishable from its control group |
| 2026-06-18 | Volume shock without a price move price | -1.33% over 21 days · t = -4.53 · n = 16,432 statistically distinguishable from its control group |
| 2026-04-17 | Cluster sale: three or more insiders insider | -0.37% over 21 days · t = -3.38 · n = 21,542 statistically distinguishable from its control group |
| 2026-03-16 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-17 | GILLIS JONATHAN CAO and Interim CFO | Grant or award | 6.0K | 0.00 | 0 |
| 2026-08-17 | GILLIS JONATHAN CAO and Interim CFO | Grant or award | 2.2K | 0.00 | 0 |
| 2026-08-17 | Foff Erin Pennock Chief Medical Officer | Grant or award | 13.4K | 0.00 | 0 |
| 2026-08-17 | Kreitzer Anatol Chief Discovery Officer | Grant or award | 6.0K | 0.00 | 0 |
| 2026-08-17 | Kroeger Christopher A. Chief Executive Officer | Grant or award | 23.1K | 0.00 | 0 |
| 2026-08-17 | Lillie James Woodruff Chief Scientific Officer | Grant or award | 7.7K | 0.00 | 0 |
| 2026-08-17 | Hanson Kristopher General Counsel | Grant or award | 7.7K | 0.00 | 0 |
| 2026-08-14 | Catalyst4, Inc. 10% owner | Open-market purchase | 4.4M | 11.38 | 50.1M |
| 2026-08-03 | Lillie James Woodruff Chief Scientific Officer | Open-market sale 10b5-1 plan | 22.1K | 12.54 | 276.9K |
| 2026-07-30 | Catalyst4, Inc. 10% owner | Open-market purchase | 1.0M | 13.00 | 13.0M |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| NOVO HOLDINGS A/S | 74.9M | 3.7M |
| FCPM III SERVICES B.V. | 65.6M | 3.2M |
| GOLDMAN SACHS GROUP INC | 40.6M | 2.0M |
| BlackRock, Inc. | 27.2M | 1.3M |
| Blue Owl Capital Holdings LP | 20.5M | 1.0M |
| Nan Fung Group Holdings Ltd | 19.7M | 971.3K |
| 5AM Venture Management, LLC | 19.3M | 950.0K |
| Sanofi | 18.5M | 912.0K |
| VANGUARD CAPITAL MANAGEMENT LLC | 14.6M | 719.8K |
| Pivotal bioVenture Partners Investment Advisor LLC | 12.4M | 611.4K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Maplight Therapeutics, Inc. (MPLT) filed form 8-K · 2026-08-13 · SEC EDGAR
Ask the AI about MPLT
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →